Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Harmony Biosciences Holdings, Inc. Market Cap
The Harmony Biosciences Holdings, Inc. (HRMY) share price is expected to increase by 22.14% over the next year. This is based on calculating the average 12-month share price estimate provided by 6 stock analysts who have covered HRMY. Price targets range from $28.00 at the low end to $56.00 at the high end. The current analyst consensus for HRMY is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 6 Wall Street analysts have assignedHRMY 4 buy ratings, 0 hold ratings, and 2 sell ratings. This means that analysts expect Harmony Biosciences Holdings, Inc. to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on HRMY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| ami fadia Needham | Buy | $53.0 | maintained | Jan 9, 2024 |
| graig suvannavejh Mizuho Securities | Buy | $33.0 | maintained | Jan 9, 2024 |
| corinne jenkins Goldman Sachs | Sell | $28.0 | maintained | Jan 8, 2024 |
| jason gerberry Bank of America Securities | Sell | $30.0 | downgraded | Jan 2, 2024 |
| david amsellem Piper Sandler | Buy | $42.0 | reiterated | Dec 8, 2023 |
| francois brisebois Oppenheimer | Buy | $56.0 | maintained | Dec 8, 2023 |
| charles duncan Cantor Fitzgerald | Buy | $49.0 | maintained | Oct 31, 2023 |
| caroline palomeque Berenberg Bank | Buy | $54.0 | initiatedcoverage | Oct 25, 2023 |
| danielle brill Raymond James | Buy | $26.0 | maintained | Oct 13, 2023 |
| madhu kumar Goldman Sachs | Hold | None | maintained | May 2, 2023 |
| chris howerton Jefferies | Buy | $62.0 | maintained | Mar 29, 2023 |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. It offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
When did it IPO
2020
Staff Count
200
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Jeffrey M. Dayno M.D.
Market Cap
$1.98B
In 2023, HRMY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that HRMY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
PTCT-USD
$25.91
MORF-USD
$37.68
NEO-USD
$14.36
ARRY-USD
$13.17
DNUT-USD
$13.32
MRCY-USD
$29.13
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
